Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Samsung BioLogics

Division of Samsung Electronics Co. Ltd.
www.samsungbiologics.com

Latest From infirst Healthcare Ltd.

Infirst Extends Mylanta Brand With Nighttime Product, Chewable Tablets

Infirst changes the Mylanta Maximum Strength lemon-mint liquid with a "smoother, creamier formulation" and adds a vanilla caramel-flavored version and another liquid product, Mylanta Tonight, featuring a honey chamomile flavor. Also new are Mylanta Gas Minis chewable anti-gas tablets.

BioPharmaceutical United States

Study Shows Antitussive Efficacy For Diphenhydramine, Less For DXM

Diphenhydramine, a common antihistamine in cough/cold OTCs, proves more effective in suppressing cough than the common antitussive dextromethorphan, researchers say. Diphenhydramine is in FDA’s antitussive OTC monograph, but marketers are criticized for not demonstrating its and other cough/cold ingredients’ efficacy in trials.

Consumer United States

Deals Shaping The Medical Industry, April 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced March 2015.

BioPharmaceutical Medical Device

J&J’s Mylanta, Mylicon Lines Return Via ‘Fixed-Term’ License With Infirst

Unlike other OTC deals J&J made since McNeil Consumer Healthcare’s quality-control problems led to widespread recalls and a consent decree with FDA, the firm is not divesting the digestive health lines. Infirst will manufacture and market the products in the U.S. for an undisclosed period before the brands return to McNeil.

Consumer United States
See All

Company Information

  • Industry
  • Contract Research, Toxicology Testing-CRO
  • Pharmaceuticals
  • Services
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Samsung-Quintiles joint venture
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • South Korea
  • Parent & Subsidiaries
  • Samsung Electronics Co. Ltd.
  • Senior Management
  • Tae Han Kim, PhD, Pres. & CEO
    Brian Hosung Min, PhD, VP, Strategic Bus. Dev.
  • Contact Info
  • Samsung BioLogics
    Phone: 2 2255 8500
    300 Songdo Bio Way
    Yeonsu-gu
    Incheon, 21987
    South Korea
Advertisement
Advertisement
UsernamePublicRestriction

Register